Rinne U K, Marttila R
Ann Neurol. 1978 Sep;4(3):263-7. doi: 10.1002/ana.410040313.
The relationship between dopamine receptor stimulation by bromocriptine or levodopa and the relief of parkinsonism was studied in 24 patients with Parkinson disease. Bromocriptine, 30 mg daily for 20 weeks, elicited an improvement in the parkinsonian clinical features, but this was less than the subsequent improvement with levodopa and benserazide, 800 mg and 200 mg daily, respectively. There was a negative correlation between the pretreatment severity of the disease or changes in cerebrospinal fluid homovanillic acid (HVA) and improvement in parkinsonian disability during bromocriptine treatment. Futhermore, it was found that clinical improvement and HVA responses in the cerebrospinal fluid after dopamine receptor stimulation by bromocriptine may predict the clinical response to levodopa.
在24例帕金森病患者中研究了用溴隐亭或左旋多巴刺激多巴胺受体与帕金森病症状缓解之间的关系。溴隐亭，每日30毫克，持续20周，使帕金森病的临床特征有所改善，但不如随后分别每日服用800毫克左旋多巴和200毫克苄丝肼的改善效果。疾病治疗前的严重程度或脑脊液高香草酸（HVA）的变化与溴隐亭治疗期间帕金森病残疾程度的改善之间存在负相关。此外，还发现溴隐亭刺激多巴胺受体后脑脊液中的临床改善和HVA反应可能预测对左旋多巴的临床反应。
